- IMT is currently offering private equities, investment funds, venture capitals and professional investors an investment opportunity to participate in its early stage of commercial development of anti-IgD mAb. The company aims to raise US$16 million in capitals to fund its Stage 1 development of the humanized of anti-IgD mAb product ready for human clinical trial that forms a tangible asset of IMT. The capital funding will be allocated to create, produce and validate a humanized prototype of anti-IgD mAb required for human clinical trials.
- IMT currently offers a 10-20% equity in IMT plus 2 seats on the Board of Directors for US$16 million in capital funding to generate and produce a humanized anti-IgD mAb prototype.
- IMT is also seeking collaborative and strategic partnerships with biotech and pharmaceutical companies with business focuses and interests in the commercialization of therapeutic mAb for immune-mediated conditions.
- For further inquiries, please contact IMT.
IgD Mab Technology (IMT) 